NCT06488716
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06488716
Title A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP | CAN | AUS

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
University of Colorado Aurora Colorado 80045-2517 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901 United States Details
Tennesse Oncology - NASH - SCRI - PPDS Chattanooga Tennessee 37404-1130 United States Details
St Vincent's Hospital Sydney Darlinghurst New South Wales 2010 Australia Details
British Columbia Cancer Agency Vancouver British Columbia V5Z 4R2 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2MR Canada Details
Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine Montreal Quebec H3T 1E2 Canada Details
Clinica Universidad de Navarra Pamplona Navarre 31008 Spain Details
Clinica Universidad de Navarra-Madrid Madrid 28027 Spain Details
Hospital Clinico Universitario de Valencia Valencia 46010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field